Cargando…
Copeptin under glucagon stimulation
Stimulation of growth hormone (GH) and adrenocorticotropic hormone (ACTH) secretion by glucagon is a standard procedure to assess pituitary dysfunction but the pathomechanism of glucagon action remains unclear. As arginine vasopressin (AVP) may act on the release of both, GH and ACTH, we tested here...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824796/ https://www.ncbi.nlm.nih.gov/pubmed/26578365 http://dx.doi.org/10.1007/s12020-015-0783-7 |
_version_ | 1782426130086625280 |
---|---|
author | Lewandowski, Krzysztof C. Lewiński, Andrzej Skowrońska-Jóźwiak, Elżbieta Stasiak, Magdalena Horzelski, Wojciech Brabant, Georg |
author_facet | Lewandowski, Krzysztof C. Lewiński, Andrzej Skowrońska-Jóźwiak, Elżbieta Stasiak, Magdalena Horzelski, Wojciech Brabant, Georg |
author_sort | Lewandowski, Krzysztof C. |
collection | PubMed |
description | Stimulation of growth hormone (GH) and adrenocorticotropic hormone (ACTH) secretion by glucagon is a standard procedure to assess pituitary dysfunction but the pathomechanism of glucagon action remains unclear. As arginine vasopressin (AVP) may act on the release of both, GH and ACTH, we tested here the role of AVP in GST by measuring a stable precursor fragment, copeptin, which is stoichiometrically secreted with AVP in a 1:1 ratio. ACTH, cortisol, GH, and copeptin were measured at 0, 60, 90, 120, 150, and 180 min during GST in 79 subjects: healthy controls (Group 1, n = 32), subjects with pituitary disease, but with adequate cortisol and GH responses during GST (Group 2, n = 29), and those with overt hypopituitarism (Group 3, n = 18). Copeptin concentrations significantly increased over baseline 150 and 180 min following glucagon stimulation in controls and patients with intact pituitary function but not in hypopituitarism. Copeptin concentrations were stimulated over time and the maximal increment correlated with ACTH, while correlations between copeptin and GH were weaker. Interestingly, copeptin as well as GH secretion was significantly attenuated when comparing subjects within the highest to those in the lowest BMI quartile (p < 0.05). Copeptin is significantly released following glucagon stimulation. As this release is BMI-dependent, the time-dependent relation between copeptin and GH may be obscured, whereas the close relation to ACTH suggests that AVP/copeptin release might be linked to the activation of the adrenal axis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s12020-015-0783-7) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4824796 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-48247962016-04-20 Copeptin under glucagon stimulation Lewandowski, Krzysztof C. Lewiński, Andrzej Skowrońska-Jóźwiak, Elżbieta Stasiak, Magdalena Horzelski, Wojciech Brabant, Georg Endocrine Original Article Stimulation of growth hormone (GH) and adrenocorticotropic hormone (ACTH) secretion by glucagon is a standard procedure to assess pituitary dysfunction but the pathomechanism of glucagon action remains unclear. As arginine vasopressin (AVP) may act on the release of both, GH and ACTH, we tested here the role of AVP in GST by measuring a stable precursor fragment, copeptin, which is stoichiometrically secreted with AVP in a 1:1 ratio. ACTH, cortisol, GH, and copeptin were measured at 0, 60, 90, 120, 150, and 180 min during GST in 79 subjects: healthy controls (Group 1, n = 32), subjects with pituitary disease, but with adequate cortisol and GH responses during GST (Group 2, n = 29), and those with overt hypopituitarism (Group 3, n = 18). Copeptin concentrations significantly increased over baseline 150 and 180 min following glucagon stimulation in controls and patients with intact pituitary function but not in hypopituitarism. Copeptin concentrations were stimulated over time and the maximal increment correlated with ACTH, while correlations between copeptin and GH were weaker. Interestingly, copeptin as well as GH secretion was significantly attenuated when comparing subjects within the highest to those in the lowest BMI quartile (p < 0.05). Copeptin is significantly released following glucagon stimulation. As this release is BMI-dependent, the time-dependent relation between copeptin and GH may be obscured, whereas the close relation to ACTH suggests that AVP/copeptin release might be linked to the activation of the adrenal axis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s12020-015-0783-7) contains supplementary material, which is available to authorized users. Springer US 2015-11-17 2016 /pmc/articles/PMC4824796/ /pubmed/26578365 http://dx.doi.org/10.1007/s12020-015-0783-7 Text en © The Author(s) 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Article Lewandowski, Krzysztof C. Lewiński, Andrzej Skowrońska-Jóźwiak, Elżbieta Stasiak, Magdalena Horzelski, Wojciech Brabant, Georg Copeptin under glucagon stimulation |
title | Copeptin under glucagon stimulation |
title_full | Copeptin under glucagon stimulation |
title_fullStr | Copeptin under glucagon stimulation |
title_full_unstemmed | Copeptin under glucagon stimulation |
title_short | Copeptin under glucagon stimulation |
title_sort | copeptin under glucagon stimulation |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824796/ https://www.ncbi.nlm.nih.gov/pubmed/26578365 http://dx.doi.org/10.1007/s12020-015-0783-7 |
work_keys_str_mv | AT lewandowskikrzysztofc copeptinunderglucagonstimulation AT lewinskiandrzej copeptinunderglucagonstimulation AT skowronskajozwiakelzbieta copeptinunderglucagonstimulation AT stasiakmagdalena copeptinunderglucagonstimulation AT horzelskiwojciech copeptinunderglucagonstimulation AT brabantgeorg copeptinunderglucagonstimulation |